Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes

Epstein–Barr virus (EBV) is the first reported human oncogenic virus and infects more than 95% of the human population worldwide. EBV latent infection in B lymphocytes is essential for viral persistence. Glycoprotein gp42 is an indispensable member of the triggering complex for EBV entry into B cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qian, Zhong, Ling, Wei, Dongmei, Zhang, Wanlin, Hong, Junping, Kang, Yinfeng, Chen, Kaiyun, Huang, Yang, Zheng, Qingbing, Xu, Miao, Zeng, Mu-Sheng, Zeng, Yi-Xin, Xia, Ningshao, Zhao, Qinjian, Krummenacher, Claude, Chen, Yixin, Zhang, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443957/
https://www.ncbi.nlm.nih.gov/pubmed/37542379
http://dx.doi.org/10.1080/22221751.2023.2245920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443957/
https://www.ncbi.nlm.nih.gov/pubmed/37542379
http://dx.doi.org/10.1080/22221751.2023.2245920

Ejemplares similares